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Abstract
Background: Kidney transplant patients suffer from vascular abnormalities and high cardiovascular event rates,
despite initial improvements post-transplantation. The nature of the progression of vascular abnormalities in the
longer term is unknown. This pilot study investigated changes in vascular abnormalities over time in stable kidney
transplant patients long after transplantation.
Methods: Brachial artery flow-mediated dilation (FMD), nitroglycerin-mediated dilation, carotid-femoral pulse wave
velocity (cf-PWV), ankle-brachial pressure index, and common carotid artery intima-media thickness (CCA-IMT) were
assessed in 18 kidney transplant patients and 17 controls at baseline and 3–6 months after.
Results: There was no difference in age (51 ± 13 vs. 46 ± 11; P = 0.19), body mass index (26 ± 5 vs. 25 ± 3; P = 0.49),
serum cholesterol (4.54 ± 0.96 vs. 5.14 ± 1.13; P = 0.10), systolic blood pressure (BP) (132 ± 12 vs. 126 ± 12; P = 0.13),
diastolic BP (82 ± 9 vs. 77 ± 8; P = 0.10), or diabetes status (3 vs. 0; P = 0.08) between transplant patients and controls.
No difference existed in vascular markers between patients and controls at baseline. In transplant patients, FMD
decreased (− 1.52 ± 2.74; P = 0.03), cf-PWV increased (0.62 ± 1.06; P = 0.03), and CCA-IMT increased (0.35 ± 0.53; P =
0.02). No changes were observed in controls.
Conclusion: Markers of vascular structure and function worsen in the post-transplant period on long-term follow-
up, which may explain the continued high cardiovascular event rates in this population.
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Background
Patients with chronic kidney disease (CKD) have a higher
burden of cardiovascular disease (CVD), including kidney
transplant recipients [1]. Although cardiovascular risk fac-
tors improve in the immediate perioperative period, the
long-term risk remains high [2, 3]. CVD is the commonest
cause of death in transplant patients with a surviving graft,
more so than infection or malignancy [4].
Endothelial dysfunction, arterial stiffness, and acceler-
ated atherosclerosis are common in stable kidney trans-
plant patients and may contribute to the high
cardiovascular event rate [3, 5, 6]. Endothelial dysfunc-
tion, a prerequisite to atherosclerosis, encompasses
numerous maladaptive alterations adversely affecting
vascular tone, haemostasis, and inflammatory processes
within the arterial wall [7]. Both traditional and non-
traditional risk factors in transplant patients can induce
endothelial dysfunction [3, 8]. Calcification of the arterial
wall is common in transplant patients and contributes to
vascular stiffness [3, 9].
The nature of the changes in these vascular abnormal-
ities in kidney transplant recipients is unknown. Previous
studies mostly examined changes in the vascular
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properties of transplant patients pre-transplantation and
immediately post-transplantation. They were not exam-
ined in stable transplant recipients long after transplant-
ation. If these changes are adverse, they may be the
result of novel risk factors post-transplantation and may
be a cause of the high cardiovascular event rate. This
pilot study investigated the changes in endothelial dys-
function, arterial stiffness, and atherosclerosis in stable
kidney transplant recipients long into the post-
transplant period.
Methods
Study population and design
Participants included patients recruited from the trans-
plantation clinic, patient relatives, and staff volunteers.
Patients were eligible if they were between 18 to 80 years
of age with stable kidney function for ≥3 months (esti-
mated glomerular filtration rate [eGFR] change < 5ml/
min/1.73m2) and have been transplanted for ≥6 months
with or without previous dialysis. Exclusion criteria in-
cluded a history of malignancy, heart failure, vasculitis,
lupus, myocardial infarction or cerebrovascular event
within 6 months or recent hospitalisation within 3
months prior to starting the study. The study was ap-
proved by the London South East Research Ethics Com-
mittee. All participants gave informed consent prior to
their inclusion in the study. Vascular parameters were
measured in a quiet vascular laboratory with a controlled
temperature of 22–24 °C at recruitment (baseline visit)
and 3–6 months after recruitment (second visit). Figure 1
demonstrates a flow chart of the study design. Vascular
parameters measured include brachial flow-mediated
dilation (FMD), nitroglycerin-mediated dilation (NMD),
carotid-femoral pulse wave velocity (cf-PWV), and com-
mon carotid artery intima-media thickness (CCA-IMT).
Participants were required to withhold taking anti-
hypertensive medications 24 h before vascular assess-
ment to prevent interference. In the absence of local
data in transplant patients we used our previous data in
CKD patients for power calculation. For pre-dialysis
CKD patients in our previous study the FMD was 3.1 ±
3.3% [10]. To demonstrate a clinically significant differ-
ence of 60% with α = 0.05 and β = 0.80, 27 patients are
needed. For CKD patients (pre-dialysis and post-kidney
transplantation) in our previous study the CCA-IMT
was 0.77 ± 0.17 [3]. To demonstrate a clinically signifi-
cant difference of 10% over 1 year with α = 0.05 and β =
0.80, 36 patients are needed. Assuming a dropout rate of
10%, 40 patients are needed. The main aim of this pilot
study was to recruit enough patients and volunteers to
demonstrate a difference in change of endothelial
function.
Clinical characteristics
A standardised data form was used by researchers to
record participants’ medical histories, including to obtain
systematic information on the presence of cardiovascular
risk factors. Weight, height, waist and hip circumference,
and two blood pressure (BP) measurements were taken.
Body mass index (BMI) and waist to hip ratio (WHR)
were calculated.
Flow-mediated dilation, nitroglycerin-mediated dilation,
common carotid artery intima-media thickness, and
carotid-femoral pulse wave velocity
Brachial FMD, NMD, and CCA-IMT were performed
as described in previous studies by our group [3]. Cf-
PWV was performed as described before [11]. Brachial
FMD and NMD were assessed using a standard High-
Definition-Imaging-3000 ultrasound system (ATL,
Bothell, WA, USA) equipped with a 12–5 MHz linear-
array transducer. Cf-PWV was assessed using the
Fig. 1 Flowchart of study design
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SphygmoCor2000 system (AtCor Medical, Sydney,
Australia). CCA-IMT was measured using a Vivid7
ultrasound machine (GE Healthcare, Wauwatosa, WI,
USA) equipped with a linear 13–5 MHz transducer.
The overall mean (standard deviation) intra-operator
variability of FMD within our department is 0.90
(0.48)% [12].
Ankle-brachial pressure index
Ankle-brachial pressure index (ABPI) was assessed with
a continuous wave Doppler instrument (8–10MHz).
The ABPI of each leg was calculated by dividing the
highest systolic BP in the desired leg between the
measurement of the dorsalis pedis and posterior tibial
artery divided by the highest systolic BP between the
two arms. The mean ABPI value for each participant
was derived from the average between the ABPI of
the right and left leg.
Laboratory measurements
Blood and urine samples were collected for biochemical
analysis at the South West London Pathology (SWLP)
services. The internal quality assurance of the SWLP ser-
vice is guaranteed by strict adherence to analytical pro-
tocols and a comprehensive internal quality control
programme. The SWLP service subscribes to all national
external quality assessment schemes for the tests they
provide and their laboratories are also registered with
the Clinical Pathology Accreditation of the United King-
dom Accreditation Service, which ensures that the ser-
vices meet the stringent requirements expected from a
pathology service. eGFR was calculated using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) 2009 equation [13].
Statistical analyses
Continuous variables were analysed with an independent
samples t-test, categorical variables using a chi-squared
test, and within-group comparisons using a paired t-test.
Bivariate correlations between continuous variables were
calculated using Pearson’s correlation coefficient (r).
Point-Biserial correlation (rpb) was used to determine
correlations between binary and continuous variables. A
two-sided P-value of < 0.05 was used to determine statis-
tical significance. Analyses were performed using SPSS
version 25.0 (SPSS Inc., Chicago, IL, USA).
Results
Eighteen kidney transplant patients and 17 healthy vol-
unteers were enrolled in the study. The mean number of
days between the first and second visit for transplant pa-
tients was 161 ± 36 days and 185 ± 52 days for controls.
The mean duration on dialysis (haemodialysis and/or
peritoneal dialysis) before transplantation was 29 ± 14
months (median 29, interquartile range [IQR] 28). The
median time since transplantation at recruitment was
86months with an IQR of 123 months. Transplant pa-
tients were taking up to 3 of 6 different immunosuppres-
sants at recruitment. The immunosuppressants used
were Tacrolimus (89%), Mycophenolate Mofetil (39%),
Prednisolone (44%), Azathioprine (22%) and Sirolimus
(6%). The aetiology of CKD in our transplant patients
were the following: autosomal dominant polycystic kid-
ney disease (4), IgA nephropathy (4), hypertension (2),
pyelonephritis (1), focal segmental glomerulosclerosis
(1), gout nephropathy (1), and type 2 diabetes mellitus
(1). Four transplant patients had an unclear aetiology to
their CKD.
Baseline parameters in study participants
Table 1 shows the baseline clinical characteristics and
circulating biomarkers in study participants. The kidney
transplant patient group had reduced eGFR, more dysli-
pidaemics, and elevated parathyroid hormone and N-
terminal-pro-brain natriuretic peptide levels. Table 2
shows the baseline vascular structure and function of
participants. No difference existed between transplant
patients and controls.
Changes in clinical, circulating biomarkers, and in
cardiovascular structure and function in study
participants
Table 1 shows changes in clinical characteristics and cir-
culating biomarkers in participants. In controls, systolic
BP (SBP) decreased, while vitamin D and corrected cal-
cium levels increased. In transplant patients, vitamin D
levels also increased while eGFR declined. Vitamin D
levels improved presumably because participants were
able to request their laboratory results and may have
started vitamin D therapy at their own initiative or in
guidance with a clinician. Vascular structure and func-
tion did not change in controls (Table 2). In transplant
patients, brachial FMD decreased (− 1.52 ± 2.74; P =
0.03), while cf-PWV (0.62 ± 1.06; P = 0.03) and CCA-
IMT increased (0.35 ± 0.53; P = 0.02) (Table 2).
Association of changes in FMD, cf-PWV, and CIMT in
kidney transplant patients
No significant correlation existed between the decline in
eGFR and changes in FMD (r = 0.21; P = 0.42), cf-PWV
(r = 0.30; P = 0.23), or CIMT (r = 0.37; P = 0.15). Changes
in FMD was associated with baseline haemoglobin (r =
0.52, P = 0.03), corrected calcium (r = 0.61, P = 0.01), and
transferrin (r = 0.53, P = 0.03). Changes in FMD were not
associated with age (r = 0.43; P = 0.08), BMI (r = 0.45;
P = 0.05), WHR (r = 0.31; P = 0.21), gender (rpb = − 0.18;
P = 0.48), DM (rpb = 0.18; P = 0.47), SBP (r = − 0.32; P =
0.07), diastolic BP (DBP) (r = − 0.03; P = 0.89), or
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smoking (r = 0.07, P = 0.79). Changes in FMD were not
associated with any other lab values in Table 1 (P >
0.05). Changes in PWV was associated with baseline
transferrin (r = 0.52, P = 0.03). Changes in cf-PWV were
not associated with age (r = 0.18; P = 0.49), BMI (r = 0.27;
P = 0.29), WHR (r = 0.14; P = 0.57), gender (rpb = 0.16;
P = 0.54), DM (rpb = − 0.14; P = 0.59), SBP (r = 0.30; P =
0.08), or DBP (r = 0.08; P = 0.64). Changes in cf-PWV
were not associated with any other lab values in Table 1
(P > 0.05). Changes in CCA-IMT was associated with
baseline phosphate (r = 0.67, P < 0.01). Changes in CCA-
IMT were not associated with age (r = − 0.10; P = 0.71),
Table 1 Clinical characteristics and circulating biomarkers in study participants
Parameter Healthy controls (n = 17) Kidney transplant patients (n = 18) Between-group comparison
Baseline Second visit P-value Baseline Second visit P-value Baseline results P-value
Age (years) 45.82 ± 10.85 NA NA 51.28 ± 13.29 NA NA 0.19
Gender M/F 5/12 NA NA 9/9 NA NA 0.21
Body mass index (kg/m2) 24.59 ± 2.59 25.00 ± 2.66 0.09 25.56 ± 5.18 24.03 ± 7.63 0.36 0.49
Waist/Hip 0.82 ± 0.07 0.80 ± 0.06 0.10 0.86 ± 0.10 0.93 ± 0.14 0.07 0.16
Systolic blood pressure (mmHg) 125.53 ± 12.39 119.76 ± 10.62 0.02 131.94 ± 11.79 130.44 ± 10.20 0.61 0.13
Diastolic blood pressure (mmHg) 77.24 ± 7.61 76.24 ± 8.70 0.64 82.17 ± 9.22 80.56 ± 7.45 0.40 0.10
Smoking status past/present/never 0/6/11 NA NA 0/4/14 NA NA 0.39
Diabetes mellitus 0 NA NA 3 NA NA 0.08
History of IHD 0 NA NA 0 NA NA NA
Dyslipidaemia 3 NA NA 10 NA NA 0.02
Haemoglobin (g/L) 134.29 ± 11.86 138.71 ± 9.31 0.02 135.33 ± 18.01 135.72 ± 15.11 0.85 0.84
Albumin (g/L) 39.35 ± 2.47 40.12 ± 2.32 0.19 38.11 ± 2.72 38.83 ± 2.96 0.34 0.17
Urea (mmol/L) 4.26 ± 0.95 4.60 ± 1.11 0.16 7.31 ± 2.15 7.83 ± 2.67 0.05 < 0.01
Creatinine (mcmol/L) 69.65 ± 16.63 69.65 ± 15.66 1.00 104.39 ± 33.68 108.94 ± 31.53 0.14 < 0.01
eGFR (mL/min/1.73m2) 97.59 ± 15.59 97.29 ± 15.55 0.83 67.61 ± 20.25 61.56 ± 19.70 0.02 < 0.01
Total cholesterol (mmol/L) 5.14 ± 1.13 5.34 ± 1.21 0.16 4.54 ± 0.96 4.84 ± 1.45 0.30 0.10
HDL (mmol/L) 1.71 ± 0.56 1.75 ± 0.62 0.51 1.69 ± 0.55 1.73 ± 0.58 0.30 0.92
LDL (mmol/L) 3.24 ± 1.71 3.07 ± 0.89 0.63 2.29 ± 0.85 2.56 ± 1.25 0.29 0.04
Total cholesterol/HDL 3.29 ± 1.27 3.32 ± 1.26 0.78 3.00 ± 1.28 3.03 ± 1.18 0.84 0.50
Non-HDL (mmol/L) 3.44 ± 1.04 3.60 ± 1.04 0.09 2.85 ± 1.06 3.11 ± 1.37 0.34 0.11
Triglyceride (mmol/L) 1.05 ± 0.58 1.05 ± 0.70 0.97 1.24 ± 0.72 1.32 ± 0.74 0.55 0.56
Glucose (mmol/L) 4.71 ± 0.39 4.82 ± 0.40 0.35 5.74 ± 1.03 5.69 ± 1.34 0.80 < 0.01
Corrected calcium (mmol/L) 2.35 ± 0.05 2.39 ± 0.07 0.03 2.46 ± 0.08 2.46 ± 0.07 0.86 < 0.01
Inorganic phosphate (mmol/L) 1.11 ± 0.13 1.17 ± 0.14 0.05 0.99 ± 0.19 1.04 ± 0.19 0.14 0.03
PTH (pmol/L) 4.98 ± 1.57 4.53 ± 1.09 0.19 8.38 ± 3.68 9.42 ± 6.46 0.31 < 0.01
Vitamin D (nmol/L) 43.65 ± 22.03 67.41 ± 30.41 < 0.01 57.56 ± 25.21 66.50 ± 27.04 0.04 0.09
Troponin T (ng/L) 2.35 ± 1.46 2.76 ± 1.72 0.13 8.33 ± 4.94 8.39 ± 4.85 0.91 < 0.01
NT-pro-BNP (ng/L) 43.65 ± 25.57 40.41 ± 40.53 0.62 190.72 ± 172.10 189.44 ± 181.07 0.96 < 0.01
hsCRP (mgl/L) 1.90 ± 3.51 1.19 ± 1.64 0.45 2.58 ± 2.95 1.66 ± 1.68 0.19 0.54
Iron (mcmol/L) 18.75 ± 6.40 21.56 ± 7.72 0.06 15.50 ± 5.87 17.44 ± 6.12 0.26 0.20
Transferrin (g/L) 2.82 ± 0.32 2.83 ± 0.36 0.78 2.18 ± 0.32 2.25 ± 0.37 0.17 0.23
Ferritin (mcmol/L) 82.69 ± 78.98 87.69 ± 73.04 0.55 452.61 ± 1179.15 291.72 ± 579.02 0.28 < 0.01
Transferrin saturation (%) 27.50 ± 11.27 31.19 ± 12.58 0.08 29.44 ± 13.17 31.61 ± 11.37 0.48 0.54
ACR (mg/mmol) 0.49 ± 1.35 0.34 ± 0.78 0.76 5.53 ± 5.46 5.58 ± 7.20 0.97 < 0.01
PCR (mg/mmol) 11.12 ± 5.13 11.35 ± 3.82 0.87 15.58 ± 8.89 17.20 ± 10.83 0.36 0.05
Legend: n number of participants, NA not applicable, M/F male/female, IHD ischaemic heart disease, eGFR estimated glomerular filtration rate, HDL high-density
lipoprotein, LDL low-density lipoprotein, PTH parathyroid hormone, NT-pro-BNP N-terminal-pro-brain natriuretic peptide, hsCRP highly sensitive C-reactive protein,
ACR albumin to creatinine ratio, PCR protein to creatinine ratio
Data presented as mean ± standard deviation
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BMI (r = − 0.08; P = 0.78), WHR (r = − 0.29; P = 0.26),
gender (rpb = 0.14; P = 0.59), DM (rpb = − 0.25; P = 0.34),
SBP (r = 0.23; P = 0.19), or DBP (r = 0.04; P = 0.81).
Changes in CCA-IMT were not associated with any
other lab values in Table 1 (P > 0.05).
Discussion
This study shows the worsening of vascular structure
and function in stable kidney transplant patients, where
FMD decreased while cf-PWV and CCA-IMT increased.
Change in eGFR was not associated with changes in
FMD, CCA-IMT, or cf-PWV. Traditional risk factors in-
cluding age, BMI, WHR, gender, DM, SBP, and DBP did
not correlate with the changes seen. Baseline haemoglo-
bin, corrected calcium, and transferrin was associated
with changes in FMD. Baseline transferrin was associ-
ated with changes in cf-PWV while baseline phosphate
was associated with changes in CCA-IMT.
CKD patients exhibit endothelial dysfunction as mea-
sured by FMD [3, 5]. In previous studies, transplantation
has been shown to improve FMD, acutely and at 12
months [14, 15]. This recovery may be due to improve-
ments in traditional and uraemia-related non-traditional
risk factors [6]. Despite this, FMD values were often still
lower compared to controls [5, 6].
CKD patients demonstrate accelerated atherosclerosis
as evidenced by high CCA-IMT [3, 6]. The impact of
renal transplantation on CCA-IMT is conflicting. One
study demonstrated CCA-IMT to progressively increase
after 2, 4, and 6 months post-transplantation [16]. An-
other reported improvements 6 months after transplant
[17]. Despite this, values are often still higher compared
to the general population [3, 17].
Cf-PWV is a marker of arterial stiffness and predicts
the appearance of CVD in CKD, including in transplant
patients [11, 18, 19]. Studies evaluating the progression
of arterial stiffness over time is conflicting in transplant
patients. One study reported no significant change at 12
months after transplantation, while another reported an
improvement [19, 20]. Bachelet-Rousseau’s group com-
pared cf-PWV progression in transplant waitlisted
patients who were eventually transplanted or were still
transplant-pending. No difference in cf-PWV was ob-
served at baseline and upon 1-year follow-up with a
short median time of 6.3 (3.8–10.1) months post-
transplantation [21]. In contrast, Strozecki’s group
showed cf-PWV to progress in transplant patients who
were enrolled much later at 36 ± 27 months post-
transplantation [22].
Most studies evaluating changes in FMD, CCA-IMT,
and cf-PWV in transplant patients do so in immediately
post-transplanted subjects. Improvements or non-
progression in these parameters shortly after transplant-
ation does not exclude a reversal in recovery. Unlike
these studies, our patients were recruited long into the
post-transplant period at a median of 86 months post-
transplantation. Different pathophysiological mecha-
nisms exist in the development of endothelial dysfunc-
tion, accelerated atherosclerosis, and arterial stiffness.
Successful kidney transplantation can eliminate import-
ant factors that contribute to the progression of these
vascular aberrations. However, during long-term follow-
up, cardiovascular risk factors often remain and some
even worsen, which may explain the progression seen.
Additionally, immunosuppression may prevent further
improvement and eventual deterioration.
Failure in graft function can explain the progression of
endothelial dysfunction in the late post-transplant period.
Elimination of ureamic milieu may be particularly import-
ant in the restoration of vascular structure and function im-
mediately after transplantation. Interestingly, we found
baseline corrected calcium to be associated with changes in
FMD and baseline phosphate to be associated with changes
in CCA-IMT. Studies have described progressively decreas-
ing FMD with greater renal impairment [3, 5]. Improve-
ments in eGFR after transplantation can explain
improvements in FMD in the newly transplanted. However,
continued functional decline after kidney transplantation
has been noted, studies have reported rates of graft function
loss ranging from − 1.90mL/min/y to − 2.38mL/min/y in
transplant recipients [23–25]. Indeed, our transplant pa-
tients demonstrated worsening kidney function at their
Table 2 Changes in cardiovascular structure and function from baseline to second visit
Parameter Healthy controls (n = 17) Kidney transplant patients (n = 18) Between-group comparison
Baseline Second visit P-value Baseline Second visit P-value Baseline results P-value
Brachial FMD (%) 4.63 ± 3.02 3.51 ± 2.73 0.33 4.34 ± 3.45 2.82 ± 2.18 0.03 0.79
Brachial NMD (%) 16.00 ± 5.47 17.17 ± 5.18 0.31 15.15 ± 6.08 15.74 ± 3.88 0.68 0.67
Cf-PWV (m/s) 6.96 ± 1.26 7.17 ± 1.50 0.51 7.83 ± 1.76 8.44 ± 2.28 0.03 0.10
Mean ABPI 1.18 ± 0.08 1.21 ± 0.11 0.43 1.27 ± 0.15 1.23 ± 0.14 0.34 0.47
Mean CCA-IMT (mm) 5.54 ± 1.08 5.73 ± 1.34 0.22 5.73 ± 0.95 6.07 ± 0.98 0.02 0.05
Legend: n number of participants, FMD flow-mediated dilation, NMD nitroglycerin-mediated dilation, Cf-PWV carotid-femoral pulse wave velocity, ABPI ankle-
brachial pressure index, CCA-IMT common carotid intima-media thickness
Data presented as mean ± SD
Junarta et al. BMC Cardiovascular Disorders            (2020) 20:6 Page 5 of 7
follow-up visit. However, we could not demonstrate
an association between the decline in eGFR and
FMD upon follow-up. We too did not demonstrate
an association between changes in cf-PWV and
eGFR. However, in contrast, associations between
PWV and eGFR are inconclusive [26, 27]. eGFR has
also been shown to be a significant independent pre-
dictor of CCA-IMT [28]. Hence, the restoration in
eGFR post-transplant can explain improvements in
CCA-IMT. In a study by Yilmaz et al., the improve-
ment in CCA-IMT in their cohort of 178 newly
transplanted patients was associated with an accom-
panying increase in eGFR [17]. Nevertheless, the de-
cline in graft function thereafter can also explain the
inevitable progression of CCA-IMT. Yet, again, al-
though we observed parallel changes in eGFR and
CCA-IMT in our transplant patients, we did not
demonstrate an association between the two. How-
ever, consider that the mean eGFR increased from
6.3 ± 4.0 mL/min/1.73 m2 to 85.8 ± 13.7 mL/min/1.73
m2 in patients from Yilmaz’ group [17]. Whereas we
only observed a decrease of 6.06 ± 9.60 mL/min/1.73
m2 upon follow-up. Correlations between CCA-IMT
and eGFR may only be seen with substantial changes
in eGFR.
It is important to consider the role of immunosuppres-
sants in enabling the progression seen. Calcineurin in-
hibitors increase endothelin levels and abrogate nitric
oxide-induced vasodilation, making them potent vaso-
constrictors [29, 30]. Additionally, they promote intra-
vascular fibrosis and cause sodium retention leading to
hypertension [30]. Hence, these unwanted effects from
immunosuppressants may impair endothelial function
and promote arterial stiffness in the long run [5, 6].
Another factor that warrants consideration is the dysli-
pidaemia seen in our transplant patients. Metabolic syn-
drome is a novel multiplex CVD risk factor that includes
dyslipidaemia, central obesity, dysglycaemia, and hyper-
tension. It is common in those with CKD, evidenced by
reports of prevalence ranging from 30% in stage 3–4
CKD to 69% in incident haemodialysis patients [31, 32].
Our transplant population had more dyslipidaemics
compared to controls. In a cohort of 198 CKD patients,
CCA-IMT was found to be closely associated with trad-
itional cardiovascular risk factors, including dyslipidae-
mia and DM [33].
Anaemia is common in CKD and its aetiology is multi-
factorial in nature. However, erythropoietin deficiency
seems to be the major factor for explaining low haemo-
globin in CKD patients. We found that baseline haemo-
globin predicted change in FMD in our transplant
patients, while baseline transferrin predicted change in
FMD and cf-PWV. Indeed, previously it has been re-
ported that haemoglobin is inversely related to FMD in
CKD patients with or without diabetes [34, 35]. In con-
trast, the specific effect of transferrin on PWV and FMD
in CKD or kidney transplant patients has not been ex-
tensively investigated in the literature.
Ultimately, our study had a small sample size, hence it
was difficult to reveal correlations between traditional
and non-traditional risk factors with the changes
observed, including uraemia, and aspects of metabolic
syndrome.
Conclusion
Our study demonstrates that progressive worsening in
surrogate markers of vascular structure and function
occur in the post-transplant period upon long-term
follow-up. Although transplantation initially alleviates
the cardiovascular burden, the vascular disease pro-
gresses in the long-term beyond the initial ‘honeymoon’
period. Since cardiovascular mortality is the commonest
cause of mortality amongst transplant patients, the
nephrology community has long sought for interventions
that could improve the adverse cardiovascular picture in
such patients. Thus, it is important to further character-
ise the nature of the changes in vascular abnormalities
in kidney transplant recipients, which this pilot study
achieves. The ultimate goal of this study is to determine
the power needed to demonstrate a difference with an
intervention on FMD, cf-PWV, and CCA-IMT in kidney
transplant patients.
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